TUMOR MARKERS СА 125 AND НЕ 4 AS PROGNOSTIC AND PREDICTIVE FACTORS IN BORDERLINE OVARIAN TUMORS
Abstract
The aim of the study was to evaluate the relationship between serum levels of tumor markers СА 125 and НЕ 4 and disease stage, histological type as well as treatment in patients with borderline ovarian tumors. Materials and methods. Thirty patients with borderline ovarian tumors were retrospectively studied. The control group consisted of 70 patients with ovarian cancer and 30 healthy women. Results. Expression levels of СА 125 and НЕ were higher in patients with borderline tumors than in healthy women. In patients with stage I-II borderline ovarian tumors, СА 125 and НЕ 4 levels were similar to those observed in patients with ovarian cancer. However, in patients with stage III borderline ovarian tumors. After completing treatment, a significant reduction in the expression of СА 125 and НЕ 4 markers occurred. Conclusion. Tumor markers HE4 and CA125 can be predictive factors for tumor response to therapy and the tool for detecting patients at high risk for ovarian cancer.
About the Authors
A. N. Vasilyev
Novosibirsk State Medical University;
Municipal Outpatient Department № 29, Novosibirsk
Russian Federation
Russian Federation
Vasilyev Andrey Nikolaevich, Post-graduate student, Oncology Department, Novosibirsk State Medical University, oncologist, Municipal Outpatient Department № 29 (Novosibirsk).
Phone: +7 913 750-84-51. E-mail: andr0005@mail.ru
S. E. Krasilnikov
Novosibirsk Regional Cancer Center;
Novosibirsk State Medical University
Russian Federation
Russian Federation
Krasilnikov Sergey Eduardovich, MD, DSc, Professor, Oncology Department, Novosibirsk State Medical University, Head of Gynecologic Oncology Department, Novosibirsk Regional Cancer Center (Novosibirsk).
Phone: +7 913 920-12-25. E-mail: professorkrasilnikov@rambler.ru
V. Е. Voitsitsky
Novosibirsk Regional Cancer Center;
Novosibirsk State Medical University
Russian Federation
Russian Federation
Voitsitsky Vladimir Evgenyevich, MD, DSc, Head of Oncology Department,NovosibirskRegionalCancerCenter, Chief Physician of Novosibirsk Regional Cancer Center.
Phone: +7 913 923-88-67.
A. V. Gerasimov
Novosibirsk Regional Cancer Center
Russian Federation
Russian Federation
Gerasimov Alexey Vladimirovich, MD, PhD, Gynecologic Oncology Department.
Phone: +7 913 952-16-17. E-mail: dr.gerasimov@yandex.ru
A. P. Kulidzhanyan
Novosibirsk Regional Cancer Center
Russian Federation
Russian Federation
Kulidzhanyan Ani Pavlikovna, oncologist, intern, Gynecologic Oncology Department.
Phone: +7 913 784-18-88. E-mail: kulidzhanyan.ani@mail.ru
Е. V. Babayants
Novosibirsk Regional Cancer Center
Russian Federation
Russian Federation
Babayants Ekaterina Vladimirovna, MD, PhD, Gynecologic Oncology Department.
Phone: +7 913 946-84-48. E-mail: babayants@rambler.ru
V. G. Sisakyan
Novosibirsk Regional Cancer Center
Russian Federation
Russian Federation
Sisakyan Virab Gegamovich, MD, PhD, Gynecologic Oncology Department.
Phone: +7 913 768-71-11. E-mail: sisakyan@mail.ruМ. I. Krylyshkin
Novosibirsk Regional Cancer Center
Russian Federation
Russian Federation
Krylyshkin Mikhail Ivanovich, oncologist, intern, Oncology Department.
Phone: +7 923 159-11-21. E-mail: krylyshkinmisha@yandex.ru
N. A. Afanasyeva
Novosibirsk Regional Cancer Center
Russian Federation
Russian Federation
Afanasyeva Natalia Alexandrovna, oncologist.
Phone: +7 913 903-24-69. E-mail: afanasieva-1977@mail.ru
A. S. Mansurova
Novosibirsk Regional Cancer Center
Russian Federation
Russian Federation
Mansurova Alfia, oncologist, intern.
Phone: +7 923 255-61- 43. E-mail: A_Mansurova@mail.ru
References
1. Bohman Ja.V. Lectures on gynecological oncology. М., 2007. 167 p. [in Russian]
2. Novikova E.G., Battalova G.Ju. Borderline ovarian tumors. М., 2007. 151 p. [in Russian]
3. Sergeeva N.S., Marshrutina N.V. General concepts of serological biomarkers and their place in oncology // Prakticheskaja onkologija. 2011. Vol. 12 (4). P. 147–154. [in Russian]
4. Tjuljandin S.A., Moiseenko V.M. Practical Oncology: Selected Lectures. СПб., 2004. 784 p. [in Russian]
5. Chernyshova A.L., Churuksaeva O.N. The role of tumor marker CA-125 in detection of ovarian cancer recurrence // Sibirskij onkologicheskij zhurnal. 2010. № 3. P. 34–37. 7
6. Bast R.C. Jr., Skates S., Lokshin A. Moore R.G. Differential diagnosis of pelvic mass: improved algorithms and novel biomarkers.// Int. J. Gynecol. Cancer 2012. Vol. 22. P. 5–8. doi: 10.1097/IGC.0b013e318251c97d.
7. Tropé С.G., Kaern J., Davidson B. Boderline ovarian tumours // Best Pract. Res. Clin. Obstet. Gynaecol. 2012. Vol. 26 (3). P. 325–336. doi: 10.1016/j.bpobgyn.2011.12.006.
8. Kalapotharakos G., Asciutto C., Henic E., Casslen B., Borgfeldt C. High preoperative blood ievels of HE 4 predicts poor prognosis in patients with ovarian cancer // J. Ovarian Res. 2012. Vol. 5 (1). P. 20. doi: 10.1186/1757-2215-5-20.
9. Moore R.G., McMeekin D.S., Brown A.K., DiSilvestro P., Miller M.C., Allard W.Jeffery, Gajewski W., Kurman R., C.Bast Jr. R., Skates S.J. A novel multiple marker bioassay utilizing HE 4 and CA 125 for the prediction of ovarian cancer in patients with a pelvic mass // Gynecol. Oncol. 2009. Vol. 112 (1). P. 40–46. doi: 10.1016/j.ygyno.2008.08.031.
Review
For citations:
Vasilyev A.N., Krasilnikov S.E., Voitsitsky V.Е., Gerasimov A.V., Kulidzhanyan A.P., Babayants Е.V., Sisakyan V.G., Krylyshkin М.I., Afanasyeva N.A., Mansurova A.S. TUMOR MARKERS СА 125 AND НЕ 4 AS PROGNOSTIC AND PREDICTIVE FACTORS IN BORDERLINE OVARIAN TUMORS. Siberian journal of oncology. 2015;1(4):39-44. (In Russ.)
Views:
25449
Email this article 
